Runping Liu

Dr. Runping Liu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Pharmacological Research
Verified
Journal Article
Closed access
XLXiaojiaoyang Li
Xiaojiaoyang Li
RSRong Sun
Rong Sun
RLRunping Liu
Runping Liu

1 November 2018 in Phytomedicine
Verified
Journal Article
Closed access
XLXiaojiaoyang Li
Xiaojiaoyang Li
XLXiaoyu Li
Xiaoyu Li
NHNana Huang
Nana Huang
RLRunping Liu
Runping Liu
RSRong Sun
Rong Sun

13 January 2025 in Theranostics
Verified
Journal Article
Open access
PDF file
HWHong Wang
Hong Wang
FZFei Zhou
Fei Zhou
WQWenqing Qin
Wenqing Qin
YYYun Yang
Yun Yang
Xiaojiaoyang LiXiaojiaoyang Li
Xiaojiaoyang Li
RLRunping Liu
Runping Liu
Cancer remains a major challenge to global public health, with rising incidence and high mortality rates. The tumor microenvironment (TME) is a complex system of immune cells, fibroblasts, extracellular matrix (ECM), and blood vessels that form a space conducive to cancer cell proliferation. Myeloid-derived suppressor cells (MDSCs) are abundant in tumors, and they drive immunosuppression through metabolic reprogramming in the TME. This review describes how metabolic pathways such as glucose metabolism, lipid metabolism, amino acid metabolism, and adenosine metabolism have a significant impact on the function of MDSCs by regulating their immunosuppressive activity and promoting their survival and expansion in tumors. The review also explores key metabolic targets in MDSCs and strategies to modulate MDSC metabolism to improve the tumor immune microenvironment and enhance anti-tumor immune responses. Understanding these pathways can provide insight into potential therapeutic targets for modulating MDSC activity and improving outcomes of cancer immunotherapies.

11 March 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
XLXiaojiaoyang Li
Xiaojiaoyang Li
JGJunde Ge
Junde Ge
YLYajing Li
Yajing Li
YCYajie Cai
Yajie Cai
QZQi Zheng
Qi Zheng
RLRunping Liu
Runping Liu
Nonalcoholic fatty liver disease (NAFLD) has become one of the most prominent causes of chronic liver diseases and malignancies. However, few therapy has been approved. Radix Bupleuri (RB) is the most frequently used herbal medicine for the treatment of liver diseases. In the current study, we aim to systemically evaluate the therapeutic effects of saikosaponin A (SSa) and saikosaponin D (SSd), the major bioactive monomers in RB, against NAFLD and to investigate the underlying mechanisms. Our results demonstrated that both SSa and SSd improved diet-induced NAFLD. Integrative lipidomic and transcriptomic analysis revealed that SSa and SSd modulated glycerolipid metabolism by regulating related genes, like Lipe and Lipg. SSd profoundly suppressed the fatty acid biosynthesis by downregulating Fasn and Acaca expression and promoted fatty acid degradation by inducing Acox1 and Cpt1a expression. Bioinformatic analysis further predicted the implication of master transcription factors, including peroxisome proliferator-activated receptor alpha (PPARα), in the protective effects of SSa and SSd. These results were further confirmed in vitro in mouse primary hepatocytes. In summary, our study uncoded the complicated mechanisms underlying the promising anti-steatosis activities of saikosaponins (SSs), and provided critical evidence inspiring the discovery of innovative therapies based on SSa and SSd for the treatment of NAFLD and related complications.

10 October 2021 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
QZQi Zheng
Qi Zheng
SLShuo Li
Shuo Li
XLXiaojiaoyang Li
Xiaojiaoyang Li
RLRunping Liu
Runping Liu
Rhei Radix et Rhizoma, also known as rhubarb or Da Huang, has been widely used as a spice and as traditional herbal medicine for centuries, and is currently marketed in China as the principal herbs in various prescriptions, such as Da-Huang-Zhe-Chong pills and Da-Huang-Qing-Wei pills. Emodin, a major bioactive anthraquinone derivative extracted from rhubarb, represents multiple health benefits in the treatment of a host of diseases, such as immune-inflammatory abnormality, tumor progression, bacterial or viral infections, and metabolic syndrome. Emerging evidence has made great strides in clarifying the multi-targeting therapeutic mechanisms underlying the efficacious therapeutic potential of emodin, including anti-inflammatory, immunomodulatory, anti-fibrosis, anti-tumor, anti-viral, anti-bacterial, and anti-diabetic properties. This comprehensive review aims to provide an updated summary of recent developments on these pharmacological efficacies and molecular mechanisms of emodin, with a focus on the underlying molecular targets and signaling networks. We also reviewed recent attempts to improve the pharmacokinetic properties and biological activities of emodin by structural modification and novel material-based targeted delivery. In conclusion, emodin still has great potential to become promising therapeutic options to immune and inflammation abnormality, organ fibrosis, common malignancy, pathogenic bacteria or virus infections, and endocrine disease or disorder. Scientifically addressing concerns regarding the poor bioavailability and vague molecular targets would significantly contribute to the widespread acceptance of rhubarb not only as a dietary supplement in food flavorings and colorings but also as a health-promoting TCM in the coming years.

1 March 2020 in Phytomedicine
Verified
Journal Article
Closed access
XLXiaojiaoyang Li
Xiaojiaoyang Li
JGJunde Ge
Junde Ge
QZQi Zheng
Qi Zheng
JZJiaxiang Zhang
Jiaxiang Zhang
RSRong Sun
Rong Sun
RLRunping Liu
Runping Liu